SETD2 and familial pancreatic carcinoma: Our work provides mechanistic insights into how tumor‐intrinsic SETD2 deficiency reshapes the immunosuppressive TME via neutrophils, thereby providing the potential use of anti‐neutrophil immunotherapy in pancreatic cancer patients with SETD2 deficiency.